SGLT2 inhibitors reduce acute kidney injury risk in patients with diabetes mellitus receiving cisplatin chemotherapy
In a retrospective study of 288 patients with diabetes mellitus receiving cisplatin, those taking SGLT2 inhibitors had a 13.9% incidence of acute kidney injury compared to 28.5% in controls (OR: 0.42; 95% CI: 0.23-0.76). The SGLT2i group also showed higher eGFR at 3 months and lower rates of hypomagnesemia and anemia.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
SGLT2 inhibitors reduce acute kidney injury risk in patients with diabetes mellitus receiving cisplatin chemotherapy The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).
The Claim
SGLT2 inhibitors reduce acute kidney injury risk in patients with diabetes mellitus receiving cisplatin chemotherapy
This conclusion is most relevant to: Patients with cancer having diabetes mellitus receiving intravenous cisplatin (n=288, median 5 infusions at 40 mg/m²).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus. (Kidney international reports, 2026) —
How It Works
The proposed biological pathway:
- ▸SGLT2 inhibitors reduce tubular cell uptake of cisplatin
- ▸Decreased cisplatin accumulation in kidney tubular cells
- ▸Reduced tubular cell injury and inflammation
- ▸Lower incidence of acute kidney injury
Who Might Benefit
Evidence fit by population:
- ▸Patients with cancer having diabetes mellitus receiving intravenous cisplatin (n=288, median 5 infusions at 40 mg/m²)
Recommended Dose
N/A (not specified in abstract)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Single-center retrospective design with potential confounding
- ▸Short median follow-up of 2 months, limiting long-term assessment
Frequently Asked Questions
What is the main finding of this study?▼
SGLT2 inhibitors were associated with a 58% reduction in odds of acute kidney injury in diabetic cancer patients receiving cisplatin.
How many patients were included?▼
288 patients (144 per group after propensity score matching).
What was the definition of acute kidney injury used?▼
A ≥50% increase in serum creatinine within 4 weeks of cisplatin therapy.
Was the difference in hyponatremia significant?▼
No, the difference in hyponatremia between groups was not statistically significant.
References
- 1.Cintrón-García JJ, Patel M, Andersen CR, Page V, Workeneh B, Mandayam S, Al-Dallal R, Abudayyeh A, Mamlouk O. “Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus..” Kidney international reports, 2026. PMID: 42179813 DOI: 10.1016/j.ekir.2026.106538